Prevalence of genetic mutations in alpha-1 antitrypsin deficiency (aatd) in patients with chronic obstructive pulmonary disease in Colombia

Table 2 Lung function - Spirometry

Variables	No mutation n = 961	Mutation n = 144	All n = 1,105	p-value
FVC post-BD in litres, median (p25-p75)	2.37 (1.85–3.09)	2.51 (1.89–3.21)	2.4 (1.88–3.1)	0.259
FVC post-BD as percentage, median (p25-p75)	80 (67–95)	83 (67-99.5)	81 (67–95)	0.434
FEV1 post-BD in litres, median (p25-p75)	1.24 (0.93–1.72)	1.22 (0.96–1.70)	1.24 (0.94–1.71)	0.871
FEV1 post-BD as percentage, median (p25-p75)	58 (43–71)	58.5 (44.5–72)	58 (44–71)	0.862
FEV1/FVC ratio, median (p25-p75)	0.55 (0.45–0.64)	0.54 (0.44–0.62)	0.55 (0.44–0.63)	0.455
COPD prediction scales
BODEx, mean ± SD	2.25 ± 1.75	2.28 ± 1.74	2.25 ± 1.75	0.847
CAT, mean ± SD	12.3 ± 7.6	11.9 ± 7.9	12.2 ± 7.6	0.624
COTE, mean ± SD	0.88 ± 1.61	0.87 ± 1.60	0.88 ± 1.61	0.907
FCI, mean ± SD	1.89 ± 1.09	1.8 ± 0.89	1.87 ± 1.06	0.398

COPD: chronic obstructive pulmonary disease; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; BD: bronchodilator; BODEx: BODE index; CAT: COPD Assessment Test; COTE: Comorbidity Test index; FCI: functional comorbidity index. Values as mean ± standard deviation or median (p25-p75) or n (%)

ISSN: 1471-2466